Souhaitez-vous accéder aux communiqués récents ?

The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients

Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Kainova Therapeutics announces positive Phase I results for DT‑9081, showing strong safety, target engagement and early anti‑tumor activity.

Esaote unveils MyLab E85 GTS ultrasound in Vienna, combining fusion imaging and ablation confirmation to boost precision in interventional radiology today.

PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...

BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS...

VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative...

BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Announced encouraging preliminary...

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

VIENNA, Austria, March 05, 2026 (GLOBE NEWSWIRE) -- Easy to transport, featuring compact size and high-quality images, developed to revolutionise and facilitate the work of interventional radiologists...